# Endo Serial Mri Pegvisomant Tumor Size

> This skill suggests serial MRI imaging to assess tumor size in patients receiving pegvisomant therapy for acromegaly. Use when initiating pegvisomant or during follow‑up to monitor for tumor growth.

- Skill: `dromlakhani/endo-serial-mri-pegvisomant-tumor-size` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-serial-mri-pegvisomant-tumor-size`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-serial-mri-pegvisomant-tumor-size/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Marketing & Growth
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-serial-mri-pegvisomant-tumor-size

---


# Serial MRI to evaluate tumor size during pegvisomant therapy

## STEP 1 — Gather Information
Obtain baseline pituitary MRI with pituitary protocol (thin slices, contrast if appropriate) and record current IGF-1 level, symptoms, and date of pegvisomant initiation.

## STEP 2 — Rule In / Rule Out
Is the patient currently receiving pegvisomant for acromegaly and without MRI contraindications (e.g., non‑MRI‑compatible device)? If yes, proceed to Step 3; if no, this skill does not apply.

## STEP 3 — Classify or Stratify
Determine time since pegvisomant start: <6 months, 6 months, 12 months, or >12 months. Schedule MRI at 6 and 12 months after initiation; if size stable at 1 year, repeat yearly.

## STEP 4 — Decide
If MRI shows tumor growth ≥2 mm or new progression, consider discontinuing pegvisomant or adding a somatostatin receptor ligand; if size is stable, continue pegvisomant and repeat imaging per the schedule.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on IGF‑1 alone to assess tumor activity; pegvisomant lowers IGF‑1 without suppressing tumor growth. Avoid MRI intervals shorter than 6 months unless symptomatic change occurs. Ensure MRI includes dynamic pituitary sequences to distinguish true growth from flow‑related artifacts.

## Concrete Clinical Example
A 48‑year‑old woman with acromegaly started pegvisomant 15 mg daily. Baseline MRI showed a 12 mm macroadenoma abutting the cavernous sinus. At 6‑month MRI size unchanged; at 12‑month MRI unchanged. She continues pegvisomant with yearly MRI surveillance.

**Source:** Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700